GLP1R and obesity due to melanocortin 4 receptor deficiency: Their use is associated with multiple metabolic benefits in people with T2D, including improved glycaemic control, blood pressure, lipid profiles, body weight and, notably, major adverse cardiovascular events.21 More recently, dual GIP and GLP-1 analogues have been developed and investigations are currently under way into the treatment of people with T2D and obesity.26